THE EXPERIMENTAL THERAPEUTICS INSTITUTE at the Icahn School of Medicine at Mount Sinai and Regeneron Pharmaceuticals Inc. entered into an agreement with the goal of accelerating the discovery of fully-human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.
FDA approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting.
SCIEX, a company focused on life science analytical technologies, announced a collaboration with the laboratory of Amanda Paulovich, of Fred Hutchinson Cancer Research Center, to make targeted proteomics in cancer research more reproducible and specific.
HUNTSMAN CANCER INSTITUTE became the first Mediso Preclinical Imaging Center of Excellence in North America.
VANDERBILT-INGRAM CANCER CENTER received an overall “exceptional” score as part of the renewal of the Cancer Center Support Grant.
As congressional leaders discuss potential ways to avert a government shutdown, which could happen in less than a week if policymakers are unable to agree to a short-term continuing resolution to keep the government running beyond Sept. 30, I remain optimistic that NIH will receive its largest annual budget increase in 12 years.
CHRISTOPH ZIELINSKI was named editor-in-chief of ESMO Open, a new open-access, peer-reviewed online journal published by the European Society of Medical Oncology.
Amgen Inc. and Xencor Inc. entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Congress must put an end to the emerging practice of “information blocking” by purveyors of electronic health record systems, American Society of Clinical Oncology urged at a Capitol Hill briefing.
ROBERT SCHREIBER and PHILIP GREENBERG were named editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the American Association for Cancer Research.
